COMPARISON OF EFFICACY AND SAFETY OF NEWER DRUGS APPROVED FOR THE TREATMENT OF MIGRAINE DISORDER: A REVIEW

• Published in: International journal of pharmacy and pharmaceutical sciences pp. 1 - 9
• Main Authors: SIVANANDY, PALANISAMY, ROSMAN, AIDIL NATASHA, SHAPHERI, AINAA DIYANA, CHEW, TENG TENG, LAU, NATALIE JIA XIN, YEONG, MICHELLE ZI YIN, ONG, MICHELLA, MEETOOA, BIBI MUNIIRAH UMMEH HAANI, NG, ELAINE, KRISHNASAMY, KARTHIKAYINI, GOVINDARAJAN, ARULKUMARAN, SHANMUGASUNDARAM, AKILA
• Format: Journal Article
• Language: English
• Published: 24.05.2020
• ISSN: 2656-0097; 0975-1491
• DOI: 10.22159/ijpps.2020v12i7.37440

Migraine is a recurrent throbbing or pulsing headache with moderate to severe pain intensity. The pain is often one side of the head with nausea and weakness symptoms. Around 12 percent of Americans, 9 percent of Asians experiences migraine and the prevalence is highest among South Koreans (22.3%). The outcome of chronic migraine treatment can be quite disheartening, causing patients to feel out of options who have tried multiple treatments with no results. Poor efficacy, tolerability and safety of migraine preventive therapy in clinical practice lead to poor compliance and failure of therapy. The mean change in number or frequency of headache is considered as the outcome measure of migraine prevention therapy. Upon comparing all migraine prevention therapy, the Fremanezumab, Eptinezumab, Galcanezumab and Erenumab were considered as the front runner in controlling the severity and frequency of migraine. Among these drugs, Erenumab was most effective in controlling the frequency of migraine episodes as it produces more than 50 percent reduction in the mean number of monthly migraine days (MMD) over week 9-week 12. In addition to drug therapy, adequate rest, balanced diet, yoga and meditation will help patients to get rid of migraine severity. A multi-dimensional approach is essential for better control over migraine symptoms.